Total amount: € 0,00
Indexed/Abstracted in: BIOSIS Previews, EMBASE, Scopus, Emerging Sources Citation Index
Online ISSN 1827-1812
Incardona V. M., Dato E., Dato A. G.
Centro di Diagnostica Cardiovascolare del Dott. Dato Achille Giuseppe & C. s.a.s., Paternò, Italia
Vernakalant (RSD1235) is a new antiarrhythmic drug that acts selectively in the atrium, targeting atrial specific channels: the Kv1.5 channel which carries IK(ur), and the Kir3.1/3.4 channel which carries IK(Ach). Vernakalant can to block Ito, late Ina, with minor blockade of IKr currents. Vernakalant is available in intravenous forms and in oral forms. In phase II and III trials, intravenous vernakalant has been shown to be effective in terminating acute onset atrial fibrillation (AF) whose duration is longer than 3 hours and shorter than 7 days. Studies to date have shown that 51% of patients were able to maintain sinus rhythm after 90 days of using oral vernakalant 50 mg/kg twice daily compared with 37% of patients receiving placebo. Vernakalant appears to be a safe drug to use, with a few side-effects being dysgeusia, paresthesias, nausea but a minimal frequency of ventricular arrhythmias.